Give your opinion on a genetically modified medicine to treat dementia
August 17, 2021
The FPS Public Health and FAMHP would like to invite you to take part in the public consultation on a clinical trial testing the genetically modified medicine PR006A to treat frontotemporal dementia with progranulin mutations (FTD-GRN).
Source: FAMHP
The public consultation will run from 28 July 2021 to 27 August 2021.
For each clinical trial application related to the use of genetically modified organisms, the authority organises a 30-day public consultation (in accordance with the Royal Decree of 21 February 2005. This gives you the opportunity, as a citizen, to share your opinion on the clinical trial application for the genetically modified medicine PR006A to treat frontotemporal dementia with progranulin mutations (FTD-GRN).